ImmunityBio, Inc.
IBRX
Classifica tra le azioni
#2233
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Prezzo delle azioni
$8.55
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$9.06B
Variazione (1 giorno)
-6.84%
Variazione (1 anno)
249.08%
Paese
US
Scambia ImmunityBio, Inc. (IBRX)
Categoria
Healthcare
Numero di azioni in circolazione per ImmunityBio, Inc. (IBRX)
Numero di azioni in circolazione al June 2026: 1.05B
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di ImmunityBio, Inc., il numero attuale di azioni in circolazione è 1.05B. Alla fine del December 2023, la società aveva 508.64M azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di ImmunityBio, Inc. (IBRX) dal 2013 al 2026
Azioni in circolazione alla fine di ogni anno
| Anno | Azioni in circolazione | Cambia |
|---|---|---|
| 2026 (TTM) | 1.05B | 50.59% |
| 2024 | 697.31M | 37.09% |
| 2023 | 508.64M | 27.19% |
| 2022 | 399.90M | 2.74% |
| 2021 | 389.23M | 1.58% |
| 2020 | 383.18M | 0.00% |
| 2019 | 383.18M | 17.88% |
| 2018 | 325.05M | 2.81% |
| 2017 | 316.15M | -3.78% |
| 2016 | 328.55M | 0.69% |
| 2015 | 326.30M | 3.35% |
| 2014 | 315.73M | 0.00% |
| 2013 | 315.73M | 0.00% |
Azioni in circolazione per aziende simili o concorrenti
| Azienda | Azioni in circolazione | Differenza | Il paese |
|---|---|---|---|
| 253.90M | -75.82% |
US
|
|
| 396.00M | -62.29% |
US
|
|
| 478.91M | -54.39% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -94.08% |
NL
|
